Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource

Abstract

With advances in genomic sequencing technology, the number of reported gene-disease relationships has rapidly expanded. However, the evidence supporting these claims varies widely, confounding accurate evaluation of genomic variation in a clinical setting. Despite the critical need to differentiate clinically valid relationships from less well-substantiated relationships, standard guidelines for such evaluation do not currently exist. The NIH-funded Clinical Genome Resource (ClinGen) has developed a framework to define and evaluate the clinical validity of gene-disease pairs across a variety of Mendelian disorders. In this manuscript we describe a proposed framework to evaluate relevant genetic and experimental evidence supporting or contradicting a gene-disease relationship, and the subsequent validation of this framework using a set of representative gene-disease pairs. The framework provides a semi-quantitative measurement for the strength of evidence of a gene-disease relationship which correlates to a qualitative classification: “Definitive”, “Strong”, “Moderate”, “Limited”, “No Reported Evidence” or “Conflicting Evidence.” Within the ClinGen structure, classifications derived using this framework are reviewed and confirmed or adjusted based on clinical expertise of appropriate disease experts. Detailed guidance for utilizing this framework and access to the curation interface is available on our website. This evidence-based, systematic method to assess the strength of gene-disease relationships will facilitate more knowledgeable utilization of genomic variants in clinical and research settings.

HDAC4 mutations cause diabetes and induce β‐cell FoxO1 nuclear exclusion

“…In the mechanism, the β‐cells dysfunction might be caused by the FoxO1 deacetylation failure due to the HDAC4 mutations. The functional evidence in combination with what was reported in previous animal model studies: the FoxO1 deacetylation affects the function of β‐cells, clearly shows that the HDAC4 mutations are likely pathogenic of childhood hyperglycemia, and the HDAC4 variants cause childhood hyperglycemia with at least limited or even moderate evidence (Strande et al, ). Our study also suggests that HDAC4‐mediated FoxO1 deacetylation could represent a novel target for pharmacotherapy, not only of decreasing glucose‐sensitive insulin secretion but also for insulin resistance.…”

The genetics of aortopathies: Hereditary thoracic aortic aneurysms and dissections

“…Resources such as the ClinGen consortium provide structured tools to evaluate the evidence behind relevant genes to inform clinical utility (Strande et al, ). In a recent classification analysis by Renard et al, 53 HTAAD gene‐disease pairs were curated by an expert team.…”

Clinical genetic testing in endocrinology: Current concepts and contemporary challenges

“…Given the current limitations of variant interpretation, a number of initiatives have been established to enhance the reliability and/or application of existing ACMG guidelines. For example, the ClinGen consortium (http://www.clinicalgenome.org) has established processes to standardize the implementation of variant interpretation criteria for specific monogenic disease genes . Variant repositories such as ClinVar, which have previously been reported to have high rates of conflicting interpretations and an inflated number of pathogenic variants, allow continual variant re‐evaluation by applying a rating system to the evidence supporting each submission .…”